Wistar Institute | Strategic Alliance Partners

The Wistar Institute is an international leader in biomedical science. With special expertise in cancer, immunology and infectious disease research and vaccine development, Wistar is dedicated to advancing basic research, translating fundamental discoveries into future therapies to benefit global health and training the next generation of scientific leaders.

Latest from Wistar Institute


The Wistar Institute Appoints Joseph Salvino, PhD, as Professor in the Molecular and Cellular Oncogenesis Program and Scientific Director of the Molecular Screening Facility

February 09, 2017

The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious diseases, and vaccines, announces the appointment of Joseph M. Salvino, PhD, as professor in the Molecular and Cellular Oncogenesis Program and Scientific Director of the Institute’s Molecular Screening Facility.

The Wistar Institute Announces GSK Visiting Professor to Promote Academic-Industry Research Collaboration, Accelerate Drug Discovery

December 22, 2016

The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Kenneth W. Hance, Ph.D., M.P.H., Director of Antibody Therapies, Immuno-Oncology & Combinations DPU at GlaxoSmithKline (GSK), as its first Visiting Professor from GSK at Wistar.

The Wistar Institute Names Ashani Weeraratna, PhD, the Ira Brind Associate Professor for Outstanding Scientific Leadership

September 10, 2016

The Wistar Institute, an international leader in cancer, immunology and infectious diseases research, is pleased to announce that Ashani Weeraratna, PhD, associate professor and program leader in the Tumor Microenvironment and Metastasis Program, has been named the Ira Brind Associate Professor.

Ashani Weeraratna on Aging and Melanoma

December 14, 2015

Ashani Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, member, The Wistar Institute Melanoma Research Center, discusses a study examining the effects of aging on Wnt/ß-catenin signaling in melanoma.

Wistar-Penn Collaboration Identifies HSP70 as Promising New Target for Melanoma Therapy

March 12, 2015

A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.

Institute Develops Fresh Bench-to-Bedside Model Through Community Ties

April 03, 2014

In more than 40 years as a National Cancer Institute (NCI)-designated cancer center-and the first center in the network devoted purely to basic research-The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.